Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 1:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 20,574 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Immunologic Disorders Clear all
Active, not recruiting Phase 3 Interventional

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT06508658
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Epcoritamab, Rituximab, Lenalidomide, Oxaliplatin, Gemcitabine
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
19
States / cities
Duarte, California • Los Angeles, California • Palm Springs, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jun 11, 2026, 1:31 AM EDT
Not yet recruiting Not applicable Interventional

Early Automated Insulin Delivery (AID) Pilot for Newly Diagnosed T1D

NCT07501338
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Tandem Automated Insulin Delivery System
Device
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 26 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jun 11, 2026, 1:31 AM EDT
Completed Phase 1 Interventional

A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma

NCT01290549
View directory record Official record
Conditions
Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Interventions
Polatuzumab Vedotin, Rituximab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
7
States / cities
Stanford, California • Sarasota, Florida • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Jun 11, 2026, 1:31 AM EDT
Completed Phase 2 Interventional Results available

An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis

NCT02049138
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Upadacitinib, Pneumococcal 13-valent conjugate vaccine (PCV-13)
Drug · Biological
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 100 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
52
States / cities
Huntsville, Alabama • Phoenix, Arizona • Hemet, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Jun 11, 2026, 1:31 AM EDT
Completed Phase 1Phase 2 Interventional

Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia

NCT00021749
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, CLL
Interventions
Oblimerson sodium, G3139
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
3
States / cities
New Hyde Park, New York • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2009 · Synced Jun 11, 2026, 1:31 AM EDT
Completed Phase 3 Interventional Results available

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)

NCT03131648
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
44
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Jun 11, 2026, 1:31 AM EDT
Completed Phase 2 Interventional

A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus

NCT05856448
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
GLPG3667, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years to 75 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
22
States / cities
Tucson, Arizona • La Jolla, California • Rancho Mirage, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 11, 2026, 1:31 AM EDT
Recruiting No phase listed Observational

Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

NCT07264426
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
Interventions
Efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jun 11, 2026, 1:31 AM EDT
Terminated Phase 2 Interventional Results available

2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis

NCT00075608
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
filgrastim, melphalan, autologous stem cell transplantation, stem cell infusion
Biological · Drug · Procedure
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Jun 11, 2026, 1:31 AM EDT
Completed Phase 1 Interventional

Lipoic Acid as a Treatment for Acute Optic Neuritis

NCT01294176
View directory record Official record
Conditions
Optic Neuritis
Interventions
Lipoic Acid
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Jun 11, 2026, 1:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Concussion Active Rehabilitation

NCT04248218
View directory record Official record
Conditions
Pediatric ALL, Concussion, Mild, Concussion, Brain, Concussion, Intermediate
Interventions
Active Rehabilitation Group/Case
Behavioral
Lead sponsor
Children's National Research Institute
Other
Eligibility
8 Years to 18 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Jun 11, 2026, 1:31 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects

NCT00432510
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
C1 esterase inhibitor [human] (C1INH-nf)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
San Diego, California • Walnut Creek, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Jun 11, 2026, 1:31 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial

NCT05006482
View directory record Official record
Conditions
Lymphoma, Malignant Solid Neoplasm
Interventions
Best Practice, Comprehensive Geriatric Assessment, Educational Intervention, Exercise Intervention, Questionnaire Administration, Tailored Intervention
Other · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
668 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
45
States / cities
Tuscaloosa, Alabama • Fremont, California • San Francisco, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jun 11, 2026, 1:31 AM EDT
Completed Phase 1 Interventional

Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer

NCT00104923
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
fenretinide
Drug
Lead sponsor
California Cancer Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
4
States / cities
Los Angeles, California • Bethesda, Maryland • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Jun 11, 2026, 1:31 AM EDT
Completed Phase 1 Interventional

Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies

NCT02543879
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma
Interventions
FT-1101, Azacitidine
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Los Angeles, California • Sarasota, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Jun 11, 2026, 1:31 AM EDT
Completed Early Phase 1 Interventional

Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

NCT00424242
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Metastatic Cancer, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Pemetrexed
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Jun 11, 2026, 1:31 AM EDT
Completed Phase 2 Interventional Results available

Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients

NCT00533442
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Rapamycin, Mycophenolate Mofetil, Tacrolimus, Steroids
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Jun 11, 2026, 1:31 AM EDT
Completed Phase 4 Interventional

Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

NCT00002386
View directory record Official record
Conditions
HIV Infections, Hemophilia A
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 11, 2026, 1:31 AM EDT
Completed Phase 1 Interventional

Effectiveness of Antiretroviral Therapy During Acute HIV Infection

NCT00705926
View directory record Official record
Conditions
HIV Infections
Interventions
Highly Active Antiretroviral Therapy (HAART), No treatment
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Jun 11, 2026, 1:31 AM EDT
Completed Phase 4 Interventional Results available

Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis

NCT01225991
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Milnacipran
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Jun 11, 2026, 1:31 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease

NCT01731691
View directory record Official record
Conditions
HIV Disease
Interventions
α1 Proteinase Inhibitor, Placebos
Biological · Drug
Lead sponsor
Institute for Human Genetics and Biochemistry
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2020 · Synced Jun 11, 2026, 1:31 AM EDT
Active, not recruiting Not applicable Interventional

iHERO Study: Insurance, Health and Economic Resources Online for Emerging Adults With Type 1 Diabetes

NCT06348160
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
iHERO Toolkit Resource
Behavioral
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 30 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Gainesville, Florida • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Jun 11, 2026, 1:31 AM EDT
Completed Not applicable Interventional

ASTHMA-Educator Mobile Application Manage Asthma

NCT03518879
View directory record Official record
Conditions
Asthma
Interventions
ASTHMA-Educator mobile application
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Jun 11, 2026, 1:31 AM EDT
Terminated No phase listed Observational

Adherence Trial With MS LifeLines ® Services

NCT01905527
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Standard Services of Group A (Group A1), Customized Services of Group A (Group A2), Group B
Other
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2015 · Synced Jun 11, 2026, 1:31 AM EDT